Long-term treatment: LUX-Lung 3, 6, 7 and 8
In the LUX-Lung 3, LUX-Lung 6 and LUX-Lung 7 studies, 10–12% of afatinib-treated* patients were long-term responders (LTRs; treated for ≥3 years).1 In LUX-Lung 7, 12% of afatinib-treated patients versus 4% of gefitinib patients were LTRs. Long-term treatment was independent of tolerability-guided dose adjustment and of the presence of brain metastases at time of enrolment. Long-term treatment with afatinib had no detrimental impact on subsequent treatment.1
Patients treated for at least 2, 2.5 and 3 years in the overall LUX-Lung 3, 6 and 7 populations1,2
Note: For LUX-Lung 7, percentages are based on total number of patients who received treatment with afatinib or gefitinib
In LUX-Lung 8, 21 out of 398 patients in the afatinib arm were long-term responders who had received at least 12 months of afatinib treatment.3 Median treatment duration in these patients was 17.6 months (range 12.3–27.6 months). Median progression-free survival (PFS) was 16.6 months (range 2.8–25.8) and median overall survival (OS) was 21.1 months (range 12.9–31.6); one patient had a complete response and six patients had a partial response.3
Schuler M, et al. Eur J Cancer 2017;72(Suppl. 1):S176-S7.
Yang JC-H, et al. Presented at the 2017 Japanese Society of Medical Oncology Annual Meeting (Abstract 70046).
Gadgeel SM, et al. Eur J Cancer 2017;72(Suppl. 1):S185.
*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: October 2018
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue